Fate Therapeutics Inc. (FATE)

$1.11

up-down-arrow $0.06 (5.71%)

As on 17-Apr-2025 16:00EDT

Fate Therapeutics Inc. (FATE) Share Price

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 1.02 High: 1.17

52 Week Range

Low: 0.66 High: 5.92

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Market capMarket cap information

    $120 Mln

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    0.4

  • Industry P/EIndustry P/E information

    --

  • Debt to EquityDebt to Equity information

    0.27

  • ROEROE information

    -0.54 %

  • ROCEROCE information

    -42.53 %

  • Div. YieldDiv. Yield information

    0 %

  • Book ValueBook Value information

    2.75

  • EPSEPS information

    -1.61

10 Years Aggregate

CFO

$-811.94 Mln

EBITDA

$-1,082.69 Mln

Net Profit

$-1,089.18 Mln

Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Fate Therapeutics (FATE)
-32.73 17.90 -11.20 -79.37 -69.14 -47.87 -14.65
BSE Sensex
0.39 6.40 1.96 7.69 10.43 20.75 10.61
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 17-Apr-2025  |  #As on 26-Oct-2023
2024
2023
2022
2021
2020
2019
2018
Fate Therapeutics (FATE)
-55.59 -62.93 -82.76 -35.65 364.64 52.53 109.14
S&P Small-Cap 600
7.01 13.89 -17.42 25.27 9.57 20.86 -9.70
BSE Sensex
8.10 18.74 4.44 21.99 15.75 14.38 5.87

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

Detailed View
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View All
loading...

loading...

loading...

3Y Avg -- 5Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peer

View All
Company
Price ($) Market Cap ($ Mln) P/E Ratio ROE
36.19 10,117.70 20.54 23.13
296.28 8,962.72 23.48 58.42
24.72 9,739.03 -- -28.77
101.38 9,903.71 30.43 14.16

Shareholding Pattern

Detailed Holdings
loading...
BLAHBLAH

About The Company

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and...  T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 12278 Scripps Summit Drive, San Diego, CA, United States, 92131  Read more

  • Founder, CEO, President & Director

    Mr. J. Scott Wolchko

  • Founder, CEO, President & Director

    Mr. J. Scott Wolchko

  • Headquarters

    San Diego, CA

  • Website

    https://www.fatetherapeutics.com

Edit peer-selector-edit
loading...
loading...

FAQs for Fate Therapeutics Inc. (FATE)

The total asset value of Fate Therapeutics Inc (FATE) stood at $ 441 Mln as on 31-Dec-24

The share price of Fate Therapeutics Inc (FATE) is $1.11 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Fate Therapeutics Inc (FATE) has given a return of -69.14% in the last 3 years.

Fate Therapeutics Inc (FATE) has a market capitalisation of $ 120 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.

Since, TTM earnings of Fate Therapeutics Inc (FATE) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Fate Therapeutics Inc (FATE) and enter the required number of quantities and click on buy to purchase the shares of Fate Therapeutics Inc (FATE).

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 12278 Scripps Summit Drive, San Diego, CA, United States, 92131

The CEO & director of Mr. J. Scott Wolchko. is Fate Therapeutics Inc (FATE), and CFO & Sr. VP is Mr. J. Scott Wolchko.

There is no promoter pledging in Fate Therapeutics Inc (FATE).

Fate Therapeutics Inc. (FATE) Ratios
Return on equity(%)
-54.21
Operating margin(%)
-1434.52
Net Margin(%)
-1366.46
Dividend yield(%)
--

No, TTM profit after tax of Fate Therapeutics Inc (FATE) was $0 Mln.